Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5673887 | 0.98 | CYP2C19 (0.35) | CYP2C19CNR2CYP1A2L3MBTL1LTA4H | |
| SCHEMBL23513707 | 0.93 | FFAR3 (0.33) | CYP2C19CNR2CYP1A2LTA4HFFAR3 | |
| Hydrochloric Acid SCHEMBL1706436 | 0.91 | FFAR3 (0.32) | CYP2C19CNR2CYP1A2LTA4HFFAR3 | |
| SCHEMBL5177286 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL842008 | 0.86 | FFAR3 (0.35) | FFAR3 | |
| SCHEMBL14374653 | 0.81 | CYP2C9 (0.32) | CYP2C19L3MBTL1CYP2C9LMNAFFAR3 | |
| SCHEMBL12670048 | 0.81 | CYP2C9 (0.32) | CYP2C19L3MBTL1CYP2C9LMNAFFAR3 | |
| SCHEMBL24946123 | 0.81 | KDM4E (0.38) | CNR2CYP1A2CYP2C9LMNAUSP2 | |
| SCHEMBL12670054 | 0.81 | CYP2C9 (0.32) | CYP2C19L3MBTL1CYP2C9LMNAFFAR3 | |
| SCHEMBL28524188 | 0.80 | CNR2 (0.39) | CYP2C19CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117813307-A | Difunctional degradants of interleukin-1 receptor related kinase and therapeutic uses thereof | 新锐思生物制药股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-114645027-A | Aminotransferase mutant from bacillus megatherium and application thereof | 上海合全药物研发有限公司 | 2022-06-21 | — | — | CN | disclosed |
| US-9096624-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| EP-1806121-A4 | ANTI-GRAYING PREPARATION | SHISEIDO CO LTD (JP) | 2008-03-12 | — | — | EP | disclosed |
| CN-101039649-A | Anti-graying preparation | SHISEIDO CO LTD (JP) | 2007-09-19 | — | — | CN | disclosed |
| JP-2006111544-A | ANTI-WHITE HAIR AGENT | SHISEIDO CO LTD | 2006-04-27 | — | — | JP | disclosed |
| WO-2006041204-A1 | ANTI-GRAYING PREPARATION | SHISEIDO COMPANY, LTD. (JP) | 2006-04-20 | — | — | WO | disclosed |
| US-6861423-B2 | Methods of treating p38 kinase-mediated disorders with pyrido[2,3-d]pyrimidin-7-one compounds | SYNTEX (U.S.A.) LLC (US) | 2005-03-01 | — | — | US | disclosed |
| US-20030153586-A1 | 7-oxo-pyridopyrimidines (I) | SYNTEX (U.S.A) LLC | 2003-08-14 | — | — | US | disclosed |
| EP-1315726-A1 | 7- OXO PYRIDOPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-04 | — | — | EP | disclosed |
| US-6506749-B2 | Mitogen-activated protein kinases inhibitors | SYNTEX (U.S.A.) LLC | 2003-01-14 | — | — | US | disclosed |
| US-20020137756-A1 | Mitogen-activated protein kinases inhibitors | SYNTEX (U.S.A.) LLC | 2002-09-26 | — | — | US | disclosed |
| WO-2002018380-A1 | 7-OXO PYRIDOPYRIMIDINES AS INHIBITORS OF A CELLULAR PROLIFERATION | F. HOFFMANN-LA ROCHE AG (CH) | 2002-03-07 | — | — | WO | disclosed |
| EP-0116347-B1 | SUBSTITUTED 1-AZASPIRO(4.5)DECANES AND 1-AZASPIRO(5.5)-UNDECANES, INTERMEDIATES AND A PROCESS FOR THEIR PREPARATION, AND THEIR USE AS MEDICAMENTS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | CYP2C19 2821/4885CNR2 4343/4885CYP1A2 3957/4885 |
| US-20020137756-A1 | Mitogen-activated protein kinases inhibitors | MAPK1, MAP3K1, CDK1 | CYP2C19 4201/4885CNR2 1925/4885CYP1A2 2786/4885 |
| US-20030153586-A1 | 7-oxo-pyridopyrimidines (I) | AR, PARP1, DPYD | CYP2C19 232/4885CNR2 1406/4885CYP1A2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.